Extended dosing intervals of ixekizumab for psoriasis: A single-center, uncontrolled, prospective study

Ye, Li‐Ran; Yan, Binjun; Chen, Xueyan; Chen, Si‐Qi; Chen, Jiaqi; Man, Xiao‐Yong

doi:10.1016/j.jaad.2021.04.093

Cited by 6 publications

(4 citation statements)

References 12 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, clinical guidelines on dose tapering of biologics in pediatric psoriasis are lacking, and standard tapering eligibility criteria and tapering strategies are not available for such cases. Based on our observations and the results of other similar reports of extended dosing intervals in adults with psoriasis ( 15 , 16 ), we extended the dosing intervals for some patients with stable conditions who achieved PASI 90 after obtaining informed consents. Regardless of adalimumab or secukinumab, a substantial number of patients could successfully maintain PASI 90 or even PASI 100 for more than half a year, and none suffered disease flares.…”

Section: Discussionmentioning

confidence: 84%

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Zheng

Yan

et al. 2022

Front. Med.

Self Cite

View full text Add to dashboard Cite

BackgroundTreatment for pediatric psoriasis is challenging because of the lack of real-world evidence, especially for biological therapies.ObjectivesThis study evaluated the efficacy and safety of biologics in children with psoriasis based on real-world evidence.MethodsPediatric psoriasis patients aged <18 years who were treated with biologics in our hospital (2020–2022) were prospectively analyzed. Patients treated with adalimumab, secukinumab, or ixekizumab were followed up for at least 16 weeks, and 22 of 38 patients completed the 52-week observation period. Dermatologist raters were blinded to ensure the reliability of the PASI, BSA, and PGA score assessments. PASI 75 or PGA 0/1 at week 12 represented an efficient indicator.ResultsThirty-eight patients (20 males and 18 females; median age, 12.6 ± 4.1 years) were enrolled, and none were lost to follow-up. All participants were diagnosed with psoriasis, including plaque psoriasis (n = 36), nail psoriasis (n = 1), and pustular psoriasis (n = 1). Within 12 weeks, all patients achieved scores above PASI 75 and PGA 0/1. The average time to reach PASI 75 was 4.3 ± 2.0, 3.2 ± 1.8, and 2.4 ± 0.4 weeks in patients using adalimumab, secukinumab, and ixekizumab, respectively, and, 27.2% (3/11), 86.4% (19/22), and 75.0% (3/4) of these patients achieved PASI 100 at week 12, respectively. Moreover, 18 of 20 patients with plaque psoriasis maintained ≥PASI 75 after 52 weeks. The most commonly reported adverse effect was upper respiratory tract infection, and no severe adverse effects were reported.ConclusionsOur real-world data demonstrated the safety and effectiveness of adalimumab, secukinumab, and ixekizumab in children with psoriasis.

show abstract

Section: Discussionmentioning

confidence: 84%

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Zheng

Yan

et al. 2022

Front. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…With the development of biologics and surgical interventions targeting different endotypes, a precision medicine approach for CRS is becoming possible [28][29][30][31]. Thus, identifying patients with distinct endotypes is important for clinical practice [32].…”

Section: Discussionmentioning

confidence: 99%

Identification of Inflammatory Endotypes by Clinical Characteristics and Nasal Secretion Biomarkers in Chronic Rhinosinusitis with Nasal Polyps

Guo,

Lu,

Wang

et al. 2023

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Introduction: The emergency of biologics and surgical techniques targeting the specific inflammatory endotype in chronic rhinosinusitis with nasal polyps (CRSwNP) asks for efficient identification of patients with different endotypes. Although mucosal IL-4, IL-5, IL-13, and IgE have been used to define type 2 (T2) inflammation, the optimal one remains unclear. In this study, we aimed to determine the optimal anchor for T2 inflammation and identify clinical characteristics and nasal secretion biomarkers predicting different endotypes in CRSwNP. Methods: Six mediators in sinonasal tissue and 36 mediators in nasal secretion samples were detected by the Bio-Plex suspension array system. Mucosal IFN-γ and IL-17A levels were used to define the T1 and T3 endotype, respectively. The efficacy of mucosal IL-4, IL-5, IL-13, and IgE to define the T2 endotype was compared. The power of clinical characteristics and nasal secretion biomarkers to predict the T1, T2, and T3 endotype was analyzed. Results: Among mucosal IL-4, IL-5, IL-13, and IgE, IL-13 was the best one to coincide with the expression of other T2 biomarkers. A combination of atopy, facial pain symptom score, ethmoid/maxillary computed tomography score ratio, and blood eosinophil percentage had a moderate predictive performance for T2 endotype (area under the receiver operating curve [AUC] = 0.815), comparable to that of nasal secretion IL-5 (AUC = 0.819). For the T3 endotype, nasal secretion IL-1Rα identified it with an AUC value of 0.756. No efficient marker for the T1 endotype was found. Conclusion: IL-13 is a primary anchor for the T2 endotype in CRSwNP. Clinical characteristics and nasal secretion biomarkers are helpful for identifying the T2 and T3 endotype of CRSwNP.

show abstract

“…Real-world studies in China have shown that treatment with biological agents enables most patients with psoriasis to reach a PASI score of 90 or 100 after the induction treatment period and shows good efficacy and safety in the treatment of special areas/special types of psoriasis. [50][51][52] In China, the types of biological agents that have been approved and used for the treatment of moderate to severe plaque psoriasis include TNF-α inhibitors, IL-17A inhibitors, IL-12/23 inhibitors, and IL-23 inhibitors (eg, etanercept, infliximab, adalimumab, secukinumab, ixekizumab, ustekinumab, and guselkumab). A variety of TNF-α inhibitor analogs have also been successively launched for marketing.…”

Section: Implementation Methods For T2t Management With Biological Ag...mentioning

confidence: 99%

Expert consensus on the treat-to-target strategy for psoriasis with biological agents in China

Chen

Cai

Chen

et al. 2023

International Journal of Dermatology and Venereology

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic, recurrent, inflammatory systemic disease that is not only characterized by skin manifestations but may also be accompanied by various comorbidities, imposing a heavy burden on patients’ physical and mental health and affecting their quality of life. Although the continuous approval of various biological agents for clinical use has provided more effective treatment options to patients with psoriasis, no consensus on the evaluation of comprehensive treatment goals has yet been established. The treat-to-target (T2T) strategy requires consideration of multiple dimensions of treatment outcomes, the development of long-term management goals, and regular assessments of treatment conditions, which are often used in the management of chronic diseases. Therefore, based on the latest consensuses and guidelines, research data, and clinical experience as well as the combination of survey results and expert group discussions, the present consensus focuses on 4 dimensions of short- and long-term integrated management goals for biological agents: alleviating skin lesions, improving quality of life, screening and managing psoriasis comorbidities, and ensuring drug safety. The implementation methods, evaluation time, treatment monitoring, and program adjustments are also herein described to achieve comprehensive management of psoriasis to the maximum extent. This consensus provides a reference for clinical practice.

show abstract

Extended dosing intervals of ixekizumab for psoriasis: A single-center, uncontrolled, prospective study

Cited by 6 publications

References 12 publications

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group

Identification of Inflammatory Endotypes by Clinical Characteristics and Nasal Secretion Biomarkers in Chronic Rhinosinusitis with Nasal Polyps

Expert consensus on the treat-to-target strategy for psoriasis with biological agents in China

Contact Info

Product

Resources

About